KR20250018169A - 이중특이적 항체 및 안구 질환의 치료 방법 - Google Patents

이중특이적 항체 및 안구 질환의 치료 방법 Download PDF

Info

Publication number
KR20250018169A
KR20250018169A KR1020247039796A KR20247039796A KR20250018169A KR 20250018169 A KR20250018169 A KR 20250018169A KR 1020247039796 A KR1020247039796 A KR 1020247039796A KR 20247039796 A KR20247039796 A KR 20247039796A KR 20250018169 A KR20250018169 A KR 20250018169A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
cfhr4
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247039796A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 피터슨
Original Assignee
브로드윙 바이오 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브로드윙 바이오 엘엘씨 filed Critical 브로드윙 바이오 엘엘씨
Publication of KR20250018169A publication Critical patent/KR20250018169A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247039796A 2022-04-29 2023-04-28 이중특이적 항체 및 안구 질환의 치료 방법 Pending KR20250018169A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336766P 2022-04-29 2022-04-29
US63/336,766 2022-04-29
PCT/US2023/020365 WO2023212298A1 (en) 2022-04-29 2023-04-28 Bispecific antibodies and methods of treating ocular disease

Publications (1)

Publication Number Publication Date
KR20250018169A true KR20250018169A (ko) 2025-02-04

Family

ID=86688568

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247039796A Pending KR20250018169A (ko) 2022-04-29 2023-04-28 이중특이적 항체 및 안구 질환의 치료 방법

Country Status (10)

Country Link
US (1) US20250346653A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514845A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025514437A (cg-RX-API-DMAC7.html)
KR (1) KR20250018169A (cg-RX-API-DMAC7.html)
CN (1) CN119487063A (cg-RX-API-DMAC7.html)
AU (1) AU2023260823A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003285A1 (cg-RX-API-DMAC7.html)
IL (1) IL316615A (cg-RX-API-DMAC7.html)
MX (1) MX2024013187A (cg-RX-API-DMAC7.html)
WO (1) WO2023212298A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024227154A1 (en) * 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
US12649790B2 (en) 2023-07-03 2026-06-09 Medicovestor, Inc. Proteins that bind SP17 including fully-human anti-SP17 antibodies
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12673991B2 (en) 2023-12-26 2026-07-07 Medicovestor, Inc. Methods of crosslinking IgG
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
JP6138018B2 (ja) 2013-10-03 2017-05-31 三菱電機株式会社 赤外線固体撮像素子
WO2016126747A1 (en) 2015-02-02 2016-08-11 Meiragtx Uk Limited Regulation of gene expression by aptamer-mediated modulation of alternative splicing
US20160346359A1 (en) 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
WO2017173043A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
WO2019126222A1 (en) 2017-12-18 2019-06-27 Spark Therapeutics, Inc. Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
US20210363192A1 (en) 2018-04-27 2021-11-25 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
WO2019217483A1 (en) 2018-05-07 2019-11-14 Spark Therapeutics, Inc. Plasmid free aav vector producing cell lines
JP7467355B2 (ja) * 2018-05-10 2024-04-15 コンプリメント・セラピューティクス・リミテッド 黄斑変性症を評価するための方法
CA3119349A1 (en) 2018-11-16 2020-05-22 Spark Therapeutics, Inc. In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodies

Also Published As

Publication number Publication date
AU2023260823A1 (en) 2024-11-14
JP2025514437A (ja) 2025-05-02
CL2024003285A1 (es) 2025-04-04
EP4514845A1 (en) 2025-03-05
WO2023212298A1 (en) 2023-11-02
MX2024013187A (es) 2025-02-10
US20250346653A1 (en) 2025-11-13
IL316615A (en) 2024-12-01
CN119487063A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
US20250346653A1 (en) Bispecific antibodies and method of treating ocular disease
JP2024501811A (ja) Ｉｌ－４ｒ及びｉｌ－３１に対する特異性を有する多重特異性抗体
JP7777632B2 (ja) 抗ｐｄ－１抗体
KR102652720B1 (ko) Vegf 및 il-1베타에 결합하는 항체 및 이의 사용 방법
TWI874532B (zh) 雙特異性抗ｃｃｌ２抗體
JP7674383B2 (ja) Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法
US20250296996A1 (en) Angiopoietin-related protein 7-specific antibodies and uses thereof
US20250289873A1 (en) Complement factor h related 4-specific antibodies and uses thereof
WO2024227154A1 (en) Complement component 3 (c3)-specific antibodies and uses thereof
CA3250574A1 (en) Bispecific antibodies and methods of treating ocular disease
RU2816476C2 (ru) Антитело, которое связывается с vegf и il-1бета, и способы применения
OA21947A (en) Angiopoietin-related protein 7-specific antibodies and uses thereof.
AU2024304442A1 (en) Mhc class i chain-related protein a (mica)-specific antibodies and uses thereof
HK40106100A (en) Bispecific anti-ccl2 antibodies
EP4562052A2 (en) Cannabinoid type 1 receptor binding proteins and uses thereof
WO2026017189A2 (zh) 抗il-31抗体、其药物组合物及用途
HK40077249A (en) Bispecific anti-ccl2 antibodies
HK40076461A (en) Antibody that binds to vegf and pdgf-b and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application